Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples ; volume:9 ; number:1 ; day:3 ; month:6 ; year:2019 ; pages:1-7 ; date:12.2019
EJNMMI Research ; 9, Heft 1 (3.6.2019), 1-7, 12.2019
- Creator
-
Schollhammer, Romain
Clermont Gallerande, Henri De
Yacoub, Mokrane
Quintyn Ranty, Marie-Laure
Barthe, Nicole
Vimont, Delphine
Hindié, Elif
Fernandez, Philippe
Morgat, Clément
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-019-0517-6
- URN
-
urn:nbn:de:101:1-2019092011003769378589
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schollhammer, Romain
- Clermont Gallerande, Henri De
- Yacoub, Mokrane
- Quintyn Ranty, Marie-Laure
- Barthe, Nicole
- Vimont, Delphine
- Hindié, Elif
- Fernandez, Philippe
- Morgat, Clément
- SpringerLink (Online service)
Other Objects (12)
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Refined chelator spacer moieties ameliorate the pharmacokinetics of PSMA-617
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007